MarketCap
Facebook
X
TelegramQuarterly report 2023-Q3
added 11-08-2023
Invitae Corporation Depreciation & Amortization 2011-2026 | NVTA
Annual Depreciation & Amortization Invitae Corporation
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 142 M | 80.5 M | 39 M | 16.2 M | 13.5 M | 9.18 M | 6.55 M | 5.32 M | 2.32 M | 928 K | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 142 M | 928 K | 31.6 M |
Quarterly Depreciation & Amortization Invitae Corporation
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.2 M | 5 M | 35 M | - | 9.7 M | 5.8 M | 27.1 M | - | 56.8 M | 35.3 M | 16.6 M | - | 23 M | 14.5 M | 6.06 M | - | 11.1 M | 6.72 M | 3.29 M | - | 10.3 M | 6.93 M | 3.43 M | - | 5.88 M | 3.49 M | 1.73 M | - | 4.93 M | 3.25 M | 1.56 M | - | 3.72 M | 2.3 M | 1.02 M | - | 1.57 M | 967 K | 471 K | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 56.8 M | 471 K | 10.4 M |
Depreciation & Amortization of other stocks in the Diagnostics research industry
| Issuer | Depreciation & Amortization | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Akumin
AKU
|
98.2 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Bioventus
BVS
|
47 M | $ 8.96 | 0.96 % | $ 597 M |  USA |
 |
Aspira Women's Health
AWH
|
264 K | - | -6.19 % | $ 10.5 M | USA |
 |
Castle Biosciences
CSTL
|
16 M | $ 25.72 | -0.43 % | $ 714 M | USA |
 |
DexCom
DXCM
|
252 M | $ 67.65 | 1.97 % | $ 26.4 B | USA |
 |
Charles River Laboratories International
CRL
|
403 M | $ 153.73 | 1.16 % | $ 7.62 B | USA |
 |
CareDx, Inc
CDNA
|
15 M | $ 17.51 | 1.1 % | $ 933 M | USA |
 |
Guardant Health
GH
|
39.7 M | $ 88.71 | 1.75 % | $ 11.1 B | USA |
 |
Accelerate Diagnostics
AXDX
|
1.7 M | - | -61.36 % | $ 2.46 M | USA |
 |
Exact Sciences Corporation
EXAS
|
125 M | $ 103.89 | 0.04 % | $ 19.6 B | USA |
 |
Global Cord Blood Corporation
CO
|
43.3 M | - | - | $ 399 M |  China |
 |
Fulgent Genetics
FLGT
|
24.9 M | $ 15.47 | 3.48 % | $ 468 M | USA |
|
Biodesix
BDSX
|
5.77 M | $ 16.58 | -4.11 % | $ 2.15 B | USA |
 |
ICON Public Limited Company
ICLR
|
488 M | $ 99.84 | 2.28 % | $ 8.24 B |  Irlanda |
 |
Anixa Biosciences
ANIX
|
38.3 K | $ 2.89 | 1.76 % | $ 93.8 K | USA |
 |
IQVIA Holdings
IQV
|
1.14 B | $ 168.66 | 2.34 % | $ 29 B | USA |
 |
Danaher Corporation
DHR
|
750 M | $ 194.7 | 1.73 % | $ 139 B | USA |
 |
Biocept
BIOC
|
1.66 M | - | -13.05 % | $ 7.29 M | USA |
 |
Heska Corporation
HSKA
|
14 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
587 K | - | -20.0 % | $ 1.06 M | USA |
 |
Illumina
ILMN
|
354 M | $ 121.25 | 1.65 % | $ 19.3 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
570 M | $ 198.2 | -0.38 % | $ 22 B | USA |
 |
QIAGEN N.V.
QGEN
|
203 M | - | - | $ 10.6 B |  Niderland |
 |
Agilent Technologies
A
|
321 M | $ 113.1 | 1.14 % | $ 34.4 B | USA |
 |
BioNano Genomics
BNGO
|
14 M | $ 1.12 | 0.9 % | $ 1.42 M | USA |
 |
DarioHealth Corp.
DRIO
|
473 K | $ 9.0 | 6.89 % | $ 255 M |  Israel |
 |
NeoGenomics
NEO
|
36.1 M | $ 8.26 | 0.18 % | $ 1.06 B | USA |
 |
Neogen Corporation
NEOG
|
119 M | $ 9.24 | 1.37 % | $ 2 B | USA |
 |
Lantheus Holdings
LNTH
|
70.1 M | $ 80.34 | 2.34 % | $ 5.42 B | USA |
 |
Pacific Biosciences of California
PACB
|
13 M | $ 1.4 | 2.94 % | $ 420 M | USA |
 |
Chembio Diagnostics
CEMI
|
2.55 M | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
161 K | - | - | $ 9.42 M | Israel |
 |
Co-Diagnostics
CODX
|
1.23 M | $ 4.4 | 101.83 % | $ 129 M | USA |
 |
Medpace Holdings
MEDP
|
27.2 M | $ 454.76 | 0.25 % | $ 13.1 B | USA |
 |
Motus GI Holdings
MOTS
|
451 K | - | -34.28 % | $ 263 K | Israel |
 |
Mettler-Toledo International
MTD
|
51.1 M | $ 1 207.42 | 0.69 % | $ 24.9 B |  Schweiz |
 |
Celcuity
CELC
|
130 K | $ 114.34 | -0.49 % | $ 4.51 B | USA |
 |
DermTech
DMTK
|
200 K | - | -11.32 % | $ 2.94 M | USA |
 |
National Research Corporation
NRC
|
7.62 M | $ 17.76 | 2.04 % | $ 398 M | USA |
 |
Enzo Biochem
ENZ
|
1.27 M | - | -8.98 % | $ 14.8 K | USA |
 |
Natera
NTRA
|
16.7 M | $ 198.56 | 0.45 % | $ 19.5 B | USA |
 |
OPKO Health
OPK
|
98.2 M | $ 1.2 | 0.42 % | $ 833 M | USA |